Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, Keita Nakaguchi, Masanori Tanaka, Takahiro Kaki, Katsuyuki Furuta, Koichi Sato, Eriko Murakami, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Yasuhiro Koh, Masanori Nakanishi, Kuninobu Kanai, Toshio Shimokawa, Nobuyuki Yamamoto
BACKGROUND: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation. METHODS: In this prospective study, hospitalized patients with advanced cancer who had dyspnea at rest (numeric rating scale, NRS≥3) and hypoxemia were enrolled. They were treated with HFNC for five days in the respiratory unit. Primary endpoint was mean change of modified Borg scale at 24 hours...
November 20, 2023: Journal of Pain and Symptom Management